Skip to main content
. Author manuscript; available in PMC: 2018 Apr 1.
Published in final edited form as: Breast Cancer Res Treat. 2017 Feb 8;162(3):511–521. doi: 10.1007/s10549-017-4132-9

Figure 3. Prognostic stratification of non-responding patients (non-pCR) by high expression of miR-125b and low expression of miR-7 in residual invasive tumor after chemotherapy.

Figure 3

(A) High expression of miR-125b (above median, >1.2) in residual invasive tumor was associated with longer overall survival of 116 vs. 77 months compared to low miR-125b (p<0.01); (B) Similarly, low expression of miR-7 (below median, <0.2) in residual invasive tumor was associated with longer overall survival of 119 vs. 83 months (p=0.03).